Exec-Edge, Author at ExecEdge - Page 3 of 143

Swarmer Targets $200M in Pro Forma Revenue Next Year – Report

Swarmer Targets $200M in Pro Forma Revenue Next Year – Report

By Karen Roman Swarmer, Inc.’s (Nasdaq: SWMR) pending acquisition ofUkrainian unmanned-ground-vehicle maker Ratel Robotics could lead to $200 million in 2027 revenue and $20 million in adjusted EBITDA, according to a research note by Lucid Capital Markets. Swarmer, which boasts...

Slate Medicines Names Kenneth Koblan as Chief Scientific Officer

Slate Medicines Names Kenneth Koblan as Chief Scientific Officer

By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief Scientific Officer and Head...

Reformation Reports Double-Digit Income & Revenue Growth

Reformation Reports Double-Digit Income & Revenue Growth

By Karen Roman Reformation Inc. (NYSE: REF) said net revenue rose 24.1% to $155.2 million compared to the year prior driven by strength across channels, and net income increased 79.4% to $12.4 million or $0.23 per diluted share. Adjusted EBITDA...

VERAXA Biotech Designates Raju Willener as CFO

VERAXA Biotech Designates Raju Willener as CFO

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener has more than...

Input your search keywords and press Enter.